Breaking News
Home / HEALTH & FITNESS / J&J and Bayer’s Xarel to cuts recurrence of dangerous blood clots in study

J&J and Bayer’s Xarel to cuts recurrence of dangerous blood clots in study

WASHINGTON (Reuters) – Longer-term use of the oral blood thinner Xarelto significantly cut the risk of recurrence of potentially life-threatening blood clots with no additional major bleeding compared with low-dose aspirin in patients at elevated risk, according to data presented on Saturday.

Check Also

Republicans weigh health bill changes as doubts mount

WASHINGTON (Reuters) - The White House and congressional leaders said on Tuesday they were weighing changes to their plan to dismantle the Obamacare health law as Republicans' questions mounted following an estimate that it would cause 14 million Americans to lose insurance next year.